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  Calcium, through its various channels involves in local, spinal and supra-spinal transmission 
of pain. In the present study, we investigated the separate and combined treatment effects of 
verapamil (a calcium channel blocker), morphine (an opioid agonist) and naloxone (an opioid 
antagonist) on pain in the orofacial region of rats. Orofacial pain was induced by subcutaneous 
(SC) injection of formalin (50 µL, 1.5%) into the left upper lip side, and the time durations spent 
face rubbing with epsilateral forepaw were recorded in three min blocks for a period of 45 min. 
Formalin induced a biphasic pattern (first phase: 0-3 min; second phase: 15-33 min) of pain. 
Intraperitoneal (IP) injections of verapamil (2 and 8 mg kg-1) and morphine (2 and 4 mg kg-1) 
suppressed orofacial pain. Co-administration of sub-analgesic doses of verapamil (0.5 mg kg-1) 
and morphine (1 mg kg-1) produced second phase analgesia. Both phases of formalin-induced 
pain were suppressed when an analgesic dose (2 mg kg-1) of verapamil co-administered with a 
sub-analgesic dose (1 mg kg-1) of morphine. The SC injection of naloxone (2 mg kg-1) alone with 
no effect on pain intensity, prevented the antinociceptive effects induced by morphine (2 mg kg-1), 
but  not  verapamil  (2  mg  kg-1).  The  obtained  results  showed  antinociceptive  effects  for 
verapamli  and  morphine  on  orofacial  pain.  Co-administrations  of  verapamil  and  morphine 
produced antinociceptive effects. It seems that opioid analgesic system may not have a role in 
the verapamil-induced antinociception.  
© 2014 Urmia University. All rights reserved. 
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 متس׌س شقن رد ل׌ماپارو زا ׌شان درد شها֩ رد ׌د׌ئو׌پا    ׌ناهد درد لدم ֩׌ –    ׌ئارحص شوم رد ׌تروص  
 
 هد׌֩چ  
نا֯ادج نامرد تارثا ام ،هعلاطم ن׌ا رد .دن֩ ׌م تلاخد درد ׌عاخن قوف و ׌عاخن ،׌عضوم لاقتنا رد ،دوخ فلتخم ׌اه لانا֩ ق׌رط زا ،م׌سل֩ ،)׌م׌سل֩ لانا֩ ر֩ولب ֩׌( ل׌ماپارو مأوت و ه    ن׌فرم
׌ناهد ه׌حان درد رب ار )׌د׌ئو׌پا تس׌نو֯اتنآ ֩׌( ناس֩ولان و )׌د׌ئو׌پا تس׌نو֯آ ֩׌( - ׌ناهد درد .م׌در֩ ׌سررب ׌ئارحص شوم ׌تروص -   ( ن׌لامرف ׌دلج ر׌ز ق׌رزت اب ׌تروص 5 / 1    ،دصرد 55  
֩رح مادنا اب تروص شلام ׌ارب هدش ׌رپس نامز تدم و داج׌ا لااب بل پچ تمس رد )رت׌لور֩׌م  تدم ׌ارب ׌ا هق׌قد هس لصاوف رد تمس نامه ׌مادق ׌ت 55    درد ׌و֯لا ֩׌ ن׌لامرف .دش تبث هق׌قد
 ׌لا رفص ق׌اقد :لوا هلحرم( ׌ا هلحرم ود 3    ق׌اقد :مود هلحرم و 15    ׌لا 33   ( ل׌ماپارو ׌قافص لخاد تاق׌رزت .در֩ داج׌ا ) 2    و 8   ( ن׌فرم و )مر֯ول׌֩ رب  مر֯ ׌ل׌م 2 و 5   ֯ول׌֩ رب  مر֯ ׌ل׌م  درد )مر
׌ناهد -   ( ل׌ماپارو درد دض ر׌ز ر׌داقم مأوت ز׌وجت .دندر֩ ف׌عضت ار ׌تروص 5 / 5   ( ن׌فرم و )مر֯ول׌֩ رب  مر֯ ׌ل׌م 5 / 5    مأوت هدافتسا رد .در֩ داج׌ا مود هلحرم درد دض رثا ֩׌ )مر֯ول׌֩ رب  مر֯ ׌ل׌م
( ل׌ماپارو رثؤم رادقم زا 2   فرم رثؤمر׌غ رادقم اب )مر֯ول׌֩ رب  مر֯ ׌ل׌م ( ن׌ 1   ( ناس֩ولان ׌دلج ر׌ز ق׌رزت .دندش ف׌عضت ׌ن׌لامرف درد هلحرم ود ره )مر֯ول׌֩ رب  مر֯ ׌ل׌م 2    هب )مر֯ول׌֩ رب  مر֯ ׌ل׌م
( ن׌فرم درد دض رثا ،درد تدش رب ׌راذ֯رثا نودب ׌ئاهنت 2    ( ل׌ماپارو هن ׌لو )مر֯ول׌֩ رب  مر֯ ׌ل׌م 2    هب ج׌اتن .در֩ راهم ار )مر֯ول׌֩ رب  مر֯ ׌ل׌م  و ل׌ماپارو ׌ارب ار درد دض تارثا هدمآ تسد
׌ناهد درد رد ن׌فرم -   ض لمع رد ׌د׌ئو׌پا درد دض متس׌س ه֩ دسر ׌م رظن هب .دش داج׌ا درد دض تارثا ن׌فرم و ل׌ماپارو مأوت ندرب را֩ هب اب .دنداد ناشن ׌تروص دشاب هتشادن ׌شقن ل׌ماپارو ׌درد د .  
:׌د׌ل֩ ׌اه هژاو   ׌ناهد درد -     ،׌تروص ف ل׌ماپارو ،ناس֩ولان ،ن׌فرم ،ن׌لامر  
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Introduction 
 
Calcium  ions  (Ca2+)  serve  as  important  mediators  of 
cell  signaling  in  both  excitable  and  non-excitable  cells. 
Elevation in intracellular Ca2+ levels triggers physiological 
responses  that  include  muscle  contraction,  hormone 
secretion, neurotransmission, activation of Ca2+-dependent 
enzymes and Ca2+-dependent gene transcription.1 Calcium 
can  enter  cells  by  several  classes  of  channels  including 
voltage-, store-, second messenger-, and receptor-gated Ca2+ 
channels.2 The voltage-gated calcium channels (VGCCs) can 
be  divided  based  on  their  structural  similarities  of  the 
channel-forming α-subunit (Cav1, Cav2 and Cav3), or their 
sensitivity to  blockade  by  pharmacological agents (L, N, 
P/Q, R and T-type). Four different isoforms exist for L-type 
calcium channels (LTCCs) including Cav1.1, Cav1.2, Cav1.3 
and Cav1.4.3   
The  LTCCs  are  widely  distributed  in  the  nervous 
system,4 and are involved in local, spinal and supra-spinal 
transduction of pain.5-7 At the level of nociceptors, LTCCs 
contributed to release of calcitonin gene related peptide 
(CGRP).8  Nimodipine,  a  LTCC  blocker,  decreased  the 
expression  of  CGRP  in  the  trigeminal  nucleus  caudalis.9 
Modulation of LTCCs altered the firing modes of thalamo-
cortical neurons and pain responses.10 The LTCCs are also 
involved  in  morphine-induced  analgesia  and  chronic 
tolerance.  The  LTCC  blockers  including  verapamil, 
diltiazem, nifedipine, nimodipine, nicardipine, flunarizine 
and  cinnarizine  have  extensively  used  for  treatment  of 
various models of pain.6  
The  orofacial  region  is  one  of  the  most  densely 
innervated (by the trigeminal nerves) areas of the body, 
which focuses some of the most common acute, chronic and 
referred  pains.11  The  orofacial  formalin  test  was  intro-
duced and completed by Clavelou et al. 12,13 This model of 
orofacial pain has been frequently used with success in the 
study of the pain originating from orofacial region.14-17  
In  the  present  study,  we  investigated  the  effects  of 
verapamil, a LTCC blocker, on formalin-induced orofacial 
pain in rats. Due to the involvement of LTCCs in morphine-
induced  analgesia,6  co-administration  of  verapamil  and 
morphine was also examined. Naloxone pretreatment was 
performed to clarify the involvement of opioid analgesic 
system in verapamil modulation of pain.  
 
Materials and Methods 
 
Animals. Healthy adult male  Wistar rats,  weighing 
250-280 g, were used in this study. Animals were maintained 
in groups of 6 per cage in a light-dark cycle (light on at 
07:00 hr) at a controlled ambient temperature (22 ± 0.5 ˚C) 
with ad libitum access to food and water. Six rats were used 
for  each  experiment.  All  experiments  were  performed 
between 12:00 and  16:00. All research and animal care 
procedures were approved by Veterinary Ethics Committee 
  of the Faculty of Veterinary Medicine of Urmia University 
and  were  performed  in  accordance  with  the  National 
Institutes  of  Health  Guide  for  Care  and  Use  of 
Laboratory Animals.  
Chemicals. Chemicals used in the present study included 
verapamil hydrochloride, morphine sulfate and naloxone 
hydrochloride.  Verapamil  and  naloxone  hydrochloride 
were  purchased  from  Sigma-Aldrich  Chemical  Co.  (St. 
Louis, USA). Morphine sulfate was purchased from Temad 
Chemical Co. (Tehran, Iran). All drugs were dissolved in 
sterile normal saline 30 min before IP injections. 
Treatment  groups.  The  animals  were  divided  into 
following groups of six rats each: 
Group  1)  This  group  received  IP  and  intraplantar 
injections of normal saline; Group 2) This group received 
IP injection of normal saline before intraplantar injection 
of formalin; Groups 3, 4 and 5) In these groups, IP injection 
of verapamil at doses of 0.5, 2 and 8 mg kg-1, respectively, 
were performed before intraplantar injection of formalin; 
Groups 6, 7 and 8) In these groups, IP injection of morphine at 
doses of 1, 2 and 4  mg kg-1,  respectively,  were performed 
before intraplantar injection of formalin; Groups 9 and 10) 
In these groups, co-administrations of verapamil at doses 
of 0.5 and 1 mg kg-1 were performed with 1 mg kg-1 of 
morphine,  respectively,  before  intraplantar  injection  of 
formalin;  Groups  11  and  12)  These  groups  received  SC 
injection  of  naloxone  (2  mg  kg-1)  with  IP  injection  of 
morphine  (2  mg  kg-1)  and  verapamil  (2  mg  kg-1), 
respectively, before intraplantar injection of formalin. 
The  SC  injection  of  naloxone  and  IP  injections  of 
verapamil and morphine were performed 35, 30 and 25 
min before intraplantar injection of formalin, respectively. 
In  the  present  study,  the  used  doses  of  verapamil, 
morphine  and  naloxone  were  designed  according  to 
previous studies in which 1-30 mg kg-1 of verapamil, 2.5-
10 mg kg-1 of morphine, and 1-2 mg kg-1 of naloxone have 
been used.5,18-20 
Orofacial pain. Orofacial pain was induced according 
to  the  method  described  by  Tamaddonfard  et  al.,16  and 
Erfanparast  et  al.17  Each  rat  was  placed  in  plexiglass 
observation  chamber  (30  ×  30  ×  30  cm)  with  a  mirror 
mounted at 45° beneath the floor to allow an unobstructed 
view  of  the  orofacial  region.  After  a  30-min  adaptation 
period,  50  µL  of  1.5%  diluted  formalin  solution  was 
subcutaneously (SC) injected into the left side of upper lip 
just lateral to the nose using a 29-gauge injection needle. 
Immediately  following  formalin  injection,  the  rat  was 
returned  into  the  observation  chamber.  The  time  each 
animal  spent  face  rubbing  with  ipsilateral  forepaw  was 
recorded (using a stopwatch), in consecutive 3-min blocks 
over a period of 45 min, and was considered as an index of 
nociception. Subcutaneous injection of formalin induced a 
stereotyped response characterized by two well distinct 
phases. In the present study, data collected between 0 and 
3 min post-formalin injection represented the first (early)  51  E. Tamaddonfard et al. Veterinary Research Forum. 2014; 5 (1) 49 - 54 
 
phase  and  data  collected  between  15  and  33  min  after 
injection of formalin represented second (late) phase.15-17    
Statistical analysis. Data obtained from 3 min blocks 
were analyzed by Excel (Version 2010; Microsoft, Redmond, 
USA)  using  factorial  ANOVA  followed  by  Duncanʼs  test. 
Data  obtained  from  the  first  and  second  phases  were 
analyzed using one-way ANOVA followed by Duncanʼs test. 
In figures, all values are expressed as the mean ± SEM. A 
value of p < 0.05 was considered statistically significant. 
 
Results 
 
Intraplantar  injection  of  normal  saline  produced 
negligible pain responses in the first (first phase: 3.5 ± 2.2 
sec)  and  ninth  (second  phase;  1.2  ±  1.0  sec)  three  min 
blocks.  The  SC  injection  of  formalin  into  the  upper  lip 
region produced pain responses in the first and 6th - 11th 
three min blocks. Therefore, formalin produced a biphasic 
pattern  (first  phase:  0-3  min  and  second  phase:  15-33 
min) of pain response in orofacial region (Figs. 1A and 1B). 
Verapamil  (0.5  mg  kg-1,  IP)  produced  no  significant 
effects  on  the  first  and  second  phases  of  pain.  The  IP 
injection of verapamil (2 mg kg-1) significantly decreased 
the intensity of the second phase of pain (p < 0.05). The first 
and second phases of pain responses were significantly 
(p  <  0.05)  suppressed  by  IP  injection  of  8  mg  kg-1  of 
verapamil (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Three min blocks (A) and first and second phases (B) of 
pain response induced by injection of normal saline and formalin 
into upper lip. * p < 0.05 compared to Ns + Ns treated group and 
other three min blocks. † p < 0.05  compared to Ns + Ns treated 
group. Ns: Normal saline. 
 
 
  Figure 3 shows the effects of morphine on the first and 
second phases of pain response induced by formalin. The 
first and second phases of pain response were not altered 
by morphine at a dose of 1 mg kg-1. Morphine at doses of 2 
and 4 mg kg-1 significantly suppressed the first and second 
phases of pain induced by formalin (p < 0.05).  
Figure 4 shows the effects of verapamil plus morphine 
on the first and second phase of pain induced by formalin.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.  2.  The  effects  of  verapamil  on  formalin-induced  orofacial 
pain response in rats. The numbers in the parenthesis show the 
doses of verapamil (mg) per kg of body weight. * p < 0.05 compared 
to Ns + Formalin treated group. Ns: Normal saline, Vera: Verapamil.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. The effects of morphine on formalin-induced orofacial pain 
response in rats. The numbers in the parenthesis show the doses 
of morphine (mg) per kg of body weight. * p < 0.05 compared to 
Ns + Formalin treated group. Ns: Normal saline, Mor: Morphine. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. The effects of co-administration of verapamil and morphine 
on formalin-induced orofacial pain response. The numbers in the 
parenthesis show the doses of verapamil and morphine (mg) per 
kg of body weight. * p < 0.05 compared to Ns + Formalin treated 
group. † p < 0.05 compared to Mor (1) + Formalin treated group. 
Ns: Normal saline, Vera: Verapamil, Mor: Morphine. 
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Co-administration  of  sub-analgesic  doses  of  verapamil 
(0.5 mg kg-1) and morphine (1 mg kg-1) with no effect on 
the first phase, significantly reduced the second phase of 
formalin-induced pain (p < 0.05). The first and second 
phases  of  formalin  pain  responses  were  significantly 
decreased by co-administration of an analgesic dose of 
verapamil (2 mg kg-1) plus a sub-analgesic dose of morphine 
(1 mg kg-1), (p < 0.05). 
Figure 5 shows the effects of naloxone alone and before 
morphine on the first and second phases of pain response 
induced by formalin. Naloxone (2 mg kg-1) alone did not 
change the intensity of the first and second phases of pain. 
Pretreatment with naloxone prior to morphine (2 mg kg-1) 
significantly  prevented  the  first  and  second  phase  pain 
suppression induced by 2 mg kg-1 of morphine (p < 0.05).  
Figure  6  shows  the  effects  of  naloxone  before 
verapamil on the first and second phases of pain response 
induced by formalin. Pre-treatment with naloxone 
(2 mg kg-1) prior to verapamil (2 mg kg-1) did not prevent 
the  antinociceptive  effects  induced  by  verapamil  in  the 
first and second phases of pain. 
 
 
 
 
 
 
 
 
 
 
 
Fig.  5.  The  effects  of  naloxone  pretreatment  on  morphine-
induced antinociception in orofacial pain response induced by 
formalin. The numbers in the  parenthesis show  the doses of 
naloxone and morphine (mg) per kg of body weight. * p < 0.05 
compared to Ns + Formalin treated group. † p < 0.05 compared 
with to Mor (1) + Formalin treated group. Ns: Normal saline, 
Mor: Morphine, Nalox: Naloxone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. The effects of naloxone pretreatment on verapamil-induced 
antinociception in orofacial pain response induced by formalin. The 
numbers  in  the  parenthesis  show  the  doses  of  verapamil, 
naloxone and morphine (mg) per kg of body weight. * p < 0.05 
compared  to  Ns  +  Formalin  treated  group.  Ns:  Normal  saline, 
Vera: Verapamil, Nalox: Naloxone. 
 
  Discussion 
 
The  present  study  shows  that  SC  injection  of  1.5% 
formalin into the upper lip produced a distinct biphasic 
(first  phase:  0-3  min  and  second  phase  (15-33  min) 
pattern  in  the  face  rubbing  performed  by  ipsilateral 
forepaw. The SC injection of formalin at the concentrations 
of 0.2-10% into the upper lip region induced a biphasic 
pattern  of  face  rubbing  in  rats.13-17  During  the  orofacial 
formalin  test,  two  distinct  phases  due  to  different 
mechanisms  of  nociception  produces,  the  first  phase  is 
associated  with  direct  stimulation  of  C-nociceptors, 
whereas  the  second  phase  is  related  to  the  release  of 
inflammatory  mediators  such  as  prostaglandins.14  Face 
rubbing with the ipsilateral forepaw due to formalin injection 
into  the  upper  lip,  has  been  mentioned  as  a  specific 
nociceptive  response.11  Some  researchers have reported 
vocalization,  grooming  and  scratching  due  to  electrical, 
mechanical, thermal and chemical (formalin) stimulation 
of the orofacial region in rats.11-22 Most of these studies 
have recorded the formalin-induced pain-related responses 
at three min blocks for a period of 45 min.11-14,16-22 The 
time schedule of five min blocks for a period of 1 hr for 
recording the formalin-induced orofacial pain have been 
also used.15,23  
In the present study, IP injection of verapamil produced 
an  antinociceptive  effect  by  reducing  formalin-induced 
face rubbing. Verapamil is a frequently prescribed calcium 
channel blocker used in treatment of hypertension, angina 
pectoralis  and  cardiac  arrhythmias.24  The  effect  of 
verapamil on pain differs depending on dosage, route of 
administration  and  pain  test  used.  The  IP  injection  of 
verapamil had no effect on acetic acid-induced visceral and 
hot plate tests of nociception in mice,25,26 whereas in the 
formalin test in rats, verapamil produced an antinociceptive 
effect.27 Intrathecal administration of verapamil produced 
no  effect  on  pain  behaviors  in  neuropathic  pain  model 
derived  from  spinal  nerve  ligation.28  There  is  not  any 
report  showing  the  effects  of  verapamil  on  formalin-
induced orofacial pain. Sukriti and Pandhi  reported that IP 
injection of nimodipine, a LTCC blocker, attenuated facial 
grooming  behavior  induced  by  SC  injection  of  formalin 
into  the  vibrissal  pad  in  rats.29  These  findings  and  the 
results of our study confirm the role of Ca2+ and its LTCCs 
in mediating inflammatory pain. 
The results of the present study showed that morphine 
via  a  naloxone-sensitive  mechanism  reduced  formalin-
induced orofacial pain. Morphine acts through mu-opioid 
receptors, and naloxone is a competitive antagonist of mu-, 
kappa- and sigma-opioid receptors with higher affinity for 
the mu-opioid receptors.30 Morphine and naloxone have 
been frequently used to explore the role of endogenous 
opioid  system  in  peripheral,  spinal  and  supra-spinal 
trigeminal pain and analgesia mechanisms. Administration 
of morphine simultaneously with formalin reduced the early 
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and late phases of formalin-induced facial pain in rats, and 
local injection of naloxone completely reversed the anti-
nociceptive effect of morphine.31 Cervicomedullary intra-
thecal injection of naloxone antagonized morphine-induced 
antinociception  in  the  orofacial  formalin  test  in  rats.32 
Microinjection of naloxone into the hippocampus prevented 
morphine-induced  antinociception  in  formalin-induced 
orofacial pain in rats.17 However, naloxone had no effect on 
the intensity of orofacial pain induced by formalin, when 
microinjected into the hippocampus and dentate gyrus.17,33 
Although,  morphine  is  a  gold  standard  analgesic 
commonly  used  to  alleviate  pain,  some  adverse  effects 
such  as  constipation,  respiratory  depression,  physical 
dependence and dizziness limit its use.30,34 Therefore, one 
might expect to eliminate these side effects by a strategy, 
which provides an effective treatment with a low dose of 
morphine. In the present study, an antinociceptive effect 
on  the  second  phase  of  pain  was  observed  when  sub-
analgesic  doses  of  verapamil  and  morphine  were  co-
administered. Both phases of formalin-induced pain were 
suppressed when an analgesic dose (2 mg kg-1) of verapamil 
co-administered with a sub-analgesic dose (1 mg kg-1) of 
morphine.  It  seems  that  a  synergistic  effect  between 
verapamil  and  morphine  is  responsible  for  their  pain 
suppressing effect in combination treatments. Intravenous 
injection of verapamil potentiated the analgesic effects of 
morphine  on  finger  pressure  and  ice  water  immersion 
tests  of  nociception  in  humans.35  Pretreatment  with 
verapamil  potentiated  the  analgesic  effects  of  morphine 
and  increased  serum  levels  of  morphine  in  mice.36 
Although  pharmacological  mechanisms  for  potentiating 
effect  of  verapamil  on  morphine  antinociception  are 
unclear, it is possible that verapamil enhances morphine-
induced  attenuation  of  nociceptive  activity  through 
blockade of Ca2+ channels. The present results also showed 
that  verapamil  via  a  naloxone-insensitive  mechanism 
produced analgesia in the formalin-induced orofacial pain. 
It has been reported that naloxone affected neither both 
the  inflammatory  changes  and  nociceptive  responses 
induced  by  formalin  nor  the  anti-inflammatory  and 
antinociceptive  effects  of  nitrendipine,  nicardipine, 
diltiazem  and  verapamil  in  rats.37  By  considering  the 
inhibitory effects of naloxone on opioid receptors,30,34 our 
findings indicated that endogenous opioid system was not 
involved in verapamil-induced antinociception. 
In conclusion, the results of the present study showed 
antinociceptive effects of verapamil and morphine through 
suppressing  both  phases  of  formalin-induced  orofacial 
pain. Co-administration of sub-analgesic doses of verapamil 
and morphine produced an antinociceptive effect only on 
second phase. Both phases of formalin-induced pain were 
suppressed  when  an  analgesic  dose  of  verapamil  co-
administered  with  a  sub-analgesic  dose  of  morphine.  It 
seems  that  verapamil-induced  antinociception  was  not 
mediated through endogenous opioid system. 
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